IL33 and lung carcinoma: In a murine model of heterotopic lung cancer expressing IL-33, ILC2-deficient mice, which were generated by reconstituting their bone marrow with RORalpha-/- hematopoietic stem cells, showed increased tumor growth and metastasis, suggesting an anti-tumor role for IL-33-activated ILC2 cells (10).